[Transdermal opioid intoxication in a patient with generalised psoriasis].
Mas-Vidal
A
A
Gómez-Díez
S
S
Salgueiro-Vázquez
M E
ME
Jimeno Demuth
F J
FJ
D000279:Administration, Cutaneous; D000369:Aged, 80 and over; D003128:Coma / Q000139:chemically induced*; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004890:Erythema / Q000150:complications / Q000378:metabolism; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000506:poisoning* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007674:Kidney Diseases / Q000139:chemically induced / Q000378:metabolism; D009270:Naloxone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D009294:Narcotics / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D010003:Osteoarthritis / Q000150:complications / Q000188:drug therapy*; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D012306:Risk; D012869:Skin Absorption; D012881:Skin Temperature
D007166:Immunosuppressive Agents; D009292:Narcotic Antagonists; D009294:Narcotics; D009270:Naloxone; D016572:Cyclosporine; D005283:Fentanyl